COMPOSITION:
Sucrabliz Suspension for oral administration contains 1 g of sucralfate per 10 mL.
DESCRIPTION:
Sucrabliz is indicated for the treatment of duodenal ulcer and for the prophylaxis of gastrointestinal hemorrhage due to stress ulceration.
ACTION:
Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine.
Although the mechanism of sucralfate’s ability to accelerate healing of duodenal ulcers remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action.
DOSAGE AND ADMINISTRATION:
Active Duodenal Ulcer. The recommended adult oral dosage for duodenal ulcer is 1 g (10 mL/2 teaspoons) four times per day. Suvrabliz should be administered on an empty stomach.
Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Elderly. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy
CONTRAINDICATIONS:
Sucrabliz is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.
PRECAUTIONS:
Precaution must be taken when considering the use of Sucrabliz in pregnant or pediatric patients, or patients of childbearing potential. Duodenal ulcer is a chronic, recurrent disease. While short-term treatment with sucralfate can result in complete healing of the ulcer, a successful course of treatment with sucralfate should not be expected to alter the post healing frequency or severity of duodenal ulceration.
Episodes of hyperglycemia have been reported in diabetic patients. Close monitoring of glycemia in diabetic patients treated with sucralfate suspension is recommended. Adjustment of the antidiabetic treatment dose during the use of sucralfate suspension might be necessary.